Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (12330)	11/25/1999 10:28:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

See changes in Calendar. "In addition, recent studies have demonstrated that rBPI-21 also enhances the activity of numerous antibiotics both in vitro and in vivo, and can overcome resistance to these antibiotics in vitro. Current data also suggest that peptides derived from rBPI-21 have broad antibacterial and antifungal activity. These data suggest that rBPI-21, or molecules derived from it, may have clinical utility in extending the use of current antibiotics and helping to control the emerging threat of antibiotic resistance." More on site. China paper is old. We been there done that.Blugreen liked it a lot. You were gone getting BPI from your pc. Having a Mac apparently I did not get any extra BPI. Were you trying to say the patent was not Non Novel?? I call any XOMA patent NON NOVEL only because they treat them as unworthy of any mention. If XOMA can't mention its' patents they must be NON NOVEL.